I have run the short form of my interpretation of recent FDA events by Provectus management. I was told that my view is essentially the company view. Here is the statement:
"The FDA meeting, which expanded the prospective indication for Melanoma and approved the application for BTD, provided the Regulatory Clarity that we, and Management, have been hearing about for so long, removing a significant impediment to the completion of licensing deals and ultimately a buyout."
In the past, shareholders heard that the reason for not doing licensing deals was that, to get a fair price, PV-10 had to have Regulatory Clarity. Apparently, the Company views the results of the FDA Meeting to provide that for prospective partners. I presume that is because they have a number of interested licensees who were waiting for the FDA information.
It therefore seems obvious that JV or licensing deals are closer to being consummated... as is the planned eventual sale of the company.
Disclosure: I am long PVCT.